Exhibit 99.1

Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update

 

 

SAN FRANCISCO, February 26, 2020 —

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on the company’s recent achievements.

 

“2019 marked another year of significant scientific, clinical, and corporate progress at Eidos. We presented positive data from the ongoing phase 2 open label extension study suggesting long-term tolerability of AG10 and stabilization of transthyretin amyloid cardiomyopathy disease measures,” said Neil Kumar PhD, chief executive officer of Eidos. “We believe the data support the hypothesis that increasing stabilization may lead to improved outcomes for ATTR patients.”

 

2019 Highlights

 

Presented interim analysis of the ongoing Phase 2 open label extension study of AG10 in patients with TTR amyloid cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation. Rates of mortality and cardiovascular hospitalization observed in exploratory analysis were lower than rates observed in placebo-treated participants in the ATTR-ACT study. Serum TTR levels, a prognostic indicator of survival, were elevated and maintained in the normal range throughout the study duration.

 

Initiated and continued enrollment of Phase 3 study of AG10 in ATTR-CM (ATTRibute-CM).

 

Published Phase 2 data of AG10 in ATTR-CM in the Journal of the American College of Cardiology (JACC).

 

Presented sub-group analysis of Phase 2 data in ATTR-CM at American College of Cardiology (ACC) Scientific Sessions.

 

Published Phase 1 data of AG10 in healthy volunteers in Clinical Pharmacology in Drug Development.

 

Granted Alexion Pharmaceuticals, Inc. an exclusive license to develop and commercialize AG10 in Japan for an upfront payment of $25.0 million and an equity investment of $25.0 million.

 

Appointed Uma Sinha, Chief Scientific Officer, to the Board of Directors.

 

Plan to initiate Phase 3 study of AG10 in ATTR-PN (ATTRibute-PN) in the first half of 2020.

 

Fourth Quarter and Full-Year 2019 Financial and Operating Results

 

Cash and cash equivalents totaled $191.2 million at December 31, 2019 compared with $157.1 million at December 31, 2018.

 

Eidos reported a net loss attributable to common stockholders of approximately $37.8 million or $1.03 per common share, for the full year 2019, as compared to a net loss attributable to common stockholders of $39.8 million or $1.86 per common share, for the prior year. The Company reported a net loss attributable to common stockholders of $19.0 million or $0.51 per common share, for the fourth quarter of 2019, as compared to a net loss attributable to common stockholders of $9.9 million or $0.27 per common share, for the fourth quarter of 2018. The increase in net loss attributable to common stockholders was driven primarily by research and development expenses related to AG10 clinical trials and other pre-clinical studies, and general and administrative expenses for operations.

Research and development expenses for the full year 2019 were $46.9 million, as compared to $28.5 million for the prior year. Research and development expenses for the fourth quarter of 2019 were $13.9 million, as compared


The following information was filed by Eidos Therapeutics, Inc. (EIDX) on Wednesday, February 26, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Eidos Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Eidos Therapeutics, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account